|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ioannidis G, Georgoulias V and Souglakos
J: How close are we to customizing chemotherapy in early non-small
cell lung cancer? Ther Adv Med Oncol. 3:185–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sadowska AM, Nowé V, Janssens A, Boeykens
E, De Backer WA and Germonpré PR: Customizing systemic therapy in
patients with advanced non-small cell lung cancer. Ther Adv Med
Oncol. 3:207–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ancuceanu RV and Istudor V:
Pharmacologically active natural compounds for lung cancer. Altern
Med Rev. 9:402–419. 2004.PubMed/NCBI
|
|
6
|
Azzam HS, Goertz C, Fritts M and Jonas WB:
Natural products and chronic hepatitis C virus. Liver Int.
27:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu W, Tang JH and Wang YD: The research
progress on Sophora flavescens Ait. Lishizhen Medicine and
Materia Medica Research. 829–830. 2006.(In Chinese).
|
|
8
|
Zhang YL: Clinical study on matrine for
the treatment of psoriasis. Hebei J Med Sci. 69:590–591. 1996.(In
Chinese).
|
|
9
|
Liu M, Liu XY and Cheng JF: Advance in the
pharmacological research on matrine. Zhongguo Zhong Yao Za Zhi.
28:801–804. 2003.(In Chinese).
|
|
10
|
Tan HR and Zhang BH: Experimental study of
the anti-inflammatory effect of matrine. Zhong Xi Yi Jie He Za Zhi.
5:108–110. 691985.(In Chinese).
|
|
11
|
Chuang CY, Xiao JG and Chiou GC: Ocular
anti-inflammatory actions of matrine. J Ocul Pharmacol. 3:129–134.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu JY, Hu JH, Zhu QG, Li FQ, Wang J and
Sun HJ: Effect of matrine on the expression of substance P receptor
and inflammatory cytokines production in human skin keratinocytes
and fibroblasts. Int Immunopharmacol. 7:816–823. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma L, Wen S, Zhan Y, He Y, Liu X and Jiang
J: Anticancer effects of the Chinese medicine matrine on murine
hepatocellular carcinoma cells. Planta Med. 74:245–251. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ho JW, Ngan Hon PL and Chim WO: Effects of
oxymatrine from Ku Shen on cancer cells. Anticancer Agents Med
Chem. 9:823–826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang H, Hou C, Zhang S, et al: Matrine
upregulates the cell cycle protein E2F-1 and triggers apoptosis via
the mitochondrial pathway in K562 cells. Eur J Pharmacol.
559:98–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Zhang H, Yu P, et al: Effects of
matrine against the growth of human lung cancer and hepatoma cells
as well as lung cancer cell migration. Cytotechnology. 59:191–200.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li LQ, Li XL, Wang L, et al: Matrine
inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7
cells. Cell Physiol Biochem. 30:631–641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu T, Song Y, Chen H, Pan S and Sun X:
Matrine inhibits proliferation and induces apoptosis of pancreatic
cancer cells in vitro and in vivo. Biol Pharm Bull. 33:1740–1745.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen K, Hu ZQ, Wang T, Guo JL, Guo H and
Ye ZQ: Matrine inhibits the proliferation of prostate cancer cells
and the activity of androgen receptor. Zhonghua Nan Ke Xue.
14:719–722. 2008.(In Chinese).
|
|
20
|
Chen K, Hu Z, Wang T, Guo H and Ye Z:
Inhibitory effect of matrine on the expression of PSA and AR in
prostate cancer cell line LNCaP. J Huazhong Univ Sci Technolog Med
Sci. 28:697–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou XH, Wei X, Huang ZS, et al: Effects
of matrine on proliferation and telomerase activity of colon cancer
SW1116 cells. Zhong Yao Cai. 32:923–925. 2009.(In Chinese).
|
|
22
|
Yu P, Liu Q, Liu K, Yagasaki K, Wu E and
Zhang G: Matrine suppresses breast cancer cell proliferation and
invasion via VEGF-Akt-NF-κB signaling. Cytotechnology. 59:219–229.
2009.PubMed/NCBI
|
|
23
|
Lu J, Luo Q, Cheng P, Liu X, Bai M and Tu
M: The role of matrine and mitogen-activated protein
kinase/extracellular signal-regulated kinase signal transduction in
the inhibition of proliferation and migration of human umbilical
vein endothelial cells induced by lung cancer cells. Zhongguo Fei
Ai Za Zhi. 12:747–752. 2009.(In Chinese).
|
|
24
|
Zhu MY, Jiang ZH, Lu YW, Guo Y and Gan JJ:
Matrine and anti-tumor drugs in inhibiting the growth of human lung
cancer cell line. Zhong Xi Yi Jie He Xue Bao. 6:163–165. 2008.(In
Chinese).
|
|
25
|
Saintigny P and Burger JA: Recent advances
in non-small cell lung cancer biology and clinical management.
Discov Med. 13:287–297. 2012.PubMed/NCBI
|
|
26
|
Aisner DL and Marshall CB: Molecular
pathology of non-small cell lung cancer: a practical guide. Am J
Clin Pathol. 138:332–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Young LC, Campling BG, Cole SP, Deeley RG
and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2
in lung cancer: correlation of protein levels with drug response
and messenger RNA levels. Clin Cancer Res. 7:1798–1804.
2001.PubMed/NCBI
|
|
28
|
Bunn PJ and Kelly K: New combinations in
the treatment of lung cancer: a time for optimism. Chest. 117(Suppl
1): S138–S143. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gori B, Ricciardi S, del Signore E, Fulvi
A and de Marinis F: Oral tyrosine kinase inhibitors in the
first-line treatment of advanced non-small cell lung cancer. Expert
Opin Ther Targets. 16(Suppl 2): S55–S60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bradham C and McClay DR: p38 MAPK in
development and cancer. Cell Cycle. 5:824–828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kumar P, Miller AI and Polverini PJ: p38
MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and
vascular endothelial growth factor protects endothelial cells
through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol
Chem. 279:43352–43360. 2004.
|
|
34
|
Park MT, Choi JA, Kim MJ, et al:
Suppression of extracellular signal-related kinase and activation
of p38 MAPK are two critical events leading to caspase-8- and
mitochondria-mediated cell death in phytosphingosine-treated human
cancer cells. J Biol Chem. 278:50624–50634. 2003. View Article : Google Scholar
|
|
35
|
Hancock JT, Desikan R and Neill SJ: Role
of reactive oxygen species in cell signalling pathways. Biochem Soc
Trans. 29:345–350. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liou GY and Storz P: Reactive oxygen
species in cancer. Free Radic Res. 44:479–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCubrey JA, Lahair MM and Franklin RA:
Reactive oxygen species-induced activation of the MAP kinase
signaling pathways. Antioxid Redox Signal. 8:1775–1789. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dixit D, Sharma V, Ghosh S, Koul N, Mishra
PK and Sen E: Manumycin inhibits STAT3, telomerase activity, and
growth of glioma cells by elevating intracellular reactive oxygen
species generation. Free Radic Biol Med. 47:364–374. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Satriano J and Schlondorff D: Activation
and attenuation of transcription factor NF-κB in mouse glomerular
mesangial cells in response to tumor necrosis factor-alpha,
immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate.
Evidence for involvement of reactive oxygen species. J Clin Invest.
94:1629–1636. 1994.
|
|
40
|
Matalon S, Hardiman KM, Jain L, et al:
Regulation of ion channel structure and function by reactive
oxygen-nitrogen species. Am J Physiol Lung Cell Mol Physiol.
285:L1184–L1189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ushio-Fukai M and Nakamura Y: Reactive
oxygen species and angiogenesis: NADPH oxidase as target for cancer
therapy. Cancer Lett. 266:37–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
